Market research
BNTC Benitec Biopharma Inc.
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 303M
- P/E ratio
- Not available
- Analyst target
- 22.8571
- Dividend yield
- Not available
- Beta
- 0.25
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 303M
- P/E ratio
- Not available
- Analyst target
- 22.8571
- Dividend yield
- Not available
- Beta
- 0.25
About
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Research context
Benitec Biopharma Inc. appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BNTC discussion.
5 years, 6 months ago
Benitec Biopharma Inc is currently in a long term uptrend where the price is trading 1.3% above its 200 day moving average.
From a valuation standpoint, the stock is 82.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 233.0.
Benitec Biopharma Inc's total revenue sank by 100.0% to $1 since the same quarter in the previous year.
Its net income has increased by 100.0% to $-3 since the same quarter in the previous year.
Finally, its free cash flow grew by 99.8% to $-6K since the same quarter in the previous year.
Based on the above factors, Benitec Biopharma Inc gets an overall score of 4/5.